TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03569605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help
Description: Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
Study: NCT03672487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: Benznidazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Sugar pill manufactured to mimic Benznidazole
Study: NCT02947841

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternating stimulation
Description: Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control cohort will receive Setting A but Setting B will be identical to Setting A.
Study: NCT02561806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03449862

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation-based clinical decision on brain CT ordering
Description: Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based clinical decision on brain CT ordering
Description: Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
Study: NCT00026182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT00752141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin chloride immediate-release
Description: capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
Study: NCT00026182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00736125

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsatile saline lavage
Description: Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
Study: NCT00752141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin chloride topical gel
Description: oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
Study: NCT04513899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW)/ registered nurse (RN) [CHW/RN]
Description: A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based Standard of Care (cbSOC) Program (control group)
Description: This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
Study: NCT00736125

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide lavage
Description: Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
Study: NCT03774212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active noise cancelling headphones
Description: The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active noise cancelling headphones
Description: The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.
Study: NCT02735590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
Study: NCT02934945

Intervention type: DRUG
Group type: OTHER
Intervention: budesonide 160μg/formoterol 4.5μg
Description: SMART regimen

Intervention type: DRUG
Group type: OTHER
Intervention: budesonide 160μg/formoterol 4.5μg
Description: SMART regimen
Study: NCT00394589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab Increased Frequency
Description: Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab Increased Dose
Description: 3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab Control
Description: Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
Study: NCT04171947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matuzalem ovule
Description: vaginal ovule with 2 mg tea extract

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vehicle ovule
Description: polyethylene glycol vaginal ovule
Study: NCT04502290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Non-invasive brain stimulation and functional electrical hand stimulation
Description: Participants will receive synchronously combined non-invasive brain stimulation (delivered via electrical/magnetic stimulation) with functional electrical stimulation (delivered via DS7A or Neuromove) of the weak hand
Study: NCT02173145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo will be given 3 times a wek over a period of 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo will be given 3 times a wek over a period of 3 months.
Study: NCT03225976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode Device
Description: The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode Device
Description: The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode Device
Description: The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Light-Emitting Diode Device
Description: The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
Study: NCT00484601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study: NCT04060732

Intervention type: DEVICE
Intervention: Flash Glucose Monitoring-FGM
Description: The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months.
Study: NCT03854019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
Description: DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
Description: DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
Study: NCT04468113

Intervention type: DEVICE
Intervention: Tumark® Vision clip
Description: Suspicious intramammary lesion is marked with clip
Study: NCT03002532

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole brain radiotherapy
Study: NCT01010009

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Trans- resveratrol
Description: All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans- resveratrol
Description: All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
Study: NCT03854019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
Study: NCT01057251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 5 mg, titrated to 20 mg, once daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg or 20 mg once daily, oral administration
Study: NCT00965120

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bradykinin receptor antagonist (HOE-140)
Description: Systemic infusion of bradykinin receptor antagonist (HOE-140).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Systemic infusion of placebo (saline).
Study: NCT03052712

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social cognition
Description: battery of tests of social cognition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social cognition
Description: battery of tests of social cognition
Study: NCT00538356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD or CRT-D with Home Monitoring feature deactivated
Description: Standard care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD or CRT-D with Home Monitoring feature activated
Description: Standard care + patient management by Home Monitoring
Study: NCT04617236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultivando La Salud
Description: A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group).
Study: NCT04457258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 FAPi-46
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Given IV
Study: NCT00663273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacid)
Description: Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
Study: NCT02804451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation with standard macintosh larygoscope; gold standard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation with standard macintosh larygoscope; gold standard
Study: NCT01010009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans- resveratrol
Description: All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (silica)
Description: All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (silica)
Description: All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (silica)
Description: All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
Study: NCT02557516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monalizumab
Description: During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monalizumab
Description: During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monalizumab
Description: During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monalizumab
Description: During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks.
Study: NCT01122017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retro-Tubercle Opening-Wedge High Tibial Osteotomy
Description: Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.